Studies have targeted certain types of sarcoma, melanoma, hepatocellular carcinoma, prostate cancer, leukemia, lymphoma, and pancreatic cancer with low expression of ASS1 and results showed that the treatment with pegylated form of arginine deiminase (ADI-PEG 20) leads to significant tumor growth inhibition [27–30]. Here, ASS1 is linked to prostate cancer.